Whee Seong Lee

Title: Whee Seong Lee: Inventor in Pharmaceutical Innovation

Introduction

Whee Seong Lee is an inventor based in Seongnam, South Korea. His patent work focuses on compounds and intermediates investigated for their potential use in preventing or treating inflammatory diseases. He is associated with Lmito Therapeutics Inc. and is credited with 2 patents.

Latest Patents

Lee’s listed patent work includes two inventions involving compounds that act as substrates for NQO1, an enzyme involved in oxidation-reduction reactions.

“Imidazoquinoline or benzoindazolone compound and intermediate for preparing same” describes compounds and related forms, along with an intermediate used in their preparation. The patent disclosure presents the compounds as substrates of NQO1 that may activate its redox activity and help reduce the expression or activity of inflammatory cytokines. It identifies potential applications in preventing or treating inflammatory diseases and other conditions associated with NQO1 activity.

“Benzoindazolone compound and intermediate thereof” concerns benzoindazolone compounds and related forms, as well as an intermediate. The disclosure describes the compounds as NQO1 substrates and proposes their potential development as medicines for preventing or treating inflammatory diseases.

Career Highlights

Lee’s listed inventions reflect a focus on pharmaceutical research, particularly the development of compounds designed to interact with NQO1. The patent disclosures describe potential therapeutic applications; they do not, by themselves, establish that the compounds have been approved or proven effective as treatments.

Collaborations

Lee is associated with Lmito Therapeutics Inc. His listed coworkers include Eun Ju Lee and In Seok Ko.

Conclusion

Whee Seong Lee’s patent portfolio centers on NQO1-related compounds and their potential applications in inflammatory disease research, highlighting his contribution to pharmaceutical innovation.